EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives

Romelia Barba Bernal, Bryan Ferrigno, Esli Medina Morales, Cristina M Castro, Daniela Goyes, Hirsh Trivedi, Vilas R Patwardhan, Alan Bonder

Turkish Journal of Gastroenterology · 2023

DOI: 10.5152/tjg.2023.22239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, 2023. Verfasst von Romelia Barba Bernal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Cholestasis, Cholangitis. Die Arbeit wurde bisher 33-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets. Cite this article as: Barba Bernal R, Ferrigno B, Medina Morales E, et al. Management of primary biliary cholangitis: Current treatment and future perspectives. Turk J Gastroenterol. 2023;34(2):89-100.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryCholestasisCholangitisHumansUrsodeoxycholic AcidCholagogues and CholereticsReceptors, Cytoplasmic and Nuclear

Substanzen

Ursodeoxycholic AcidCholagogues and CholereticsReceptors, Cytoplasmic and Nuclear

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Loyola Medicine, MacNeal Hospital, Berwyn, IL, USA.

Zitieren

APA

Barba Bernal, R., Ferrigno, B., Medina Morales, E., Castro, C. M., Goyes, D., Trivedi, H., Patwardhan, V. R., & Bonder, A. (2023). Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2023.22239

Vancouver

Barba Bernal R, Ferrigno B, Medina Morales E, Castro CM, Goyes D, Trivedi H, et al. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives. Turkish Journal of Gastroenterology. 2023. doi:10.5152/tjg.2023.22239

BibTeX
@article{BarbaBernal2023,
  author = {Barba Bernal, Romelia and Ferrigno, Bryan and Medina Morales, Esli and Castro, Cristina M and Goyes, Daniela and Trivedi, Hirsh and Patwardhan, Vilas R and Bonder, Alan},
  title = {Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives},
  journal = {Turkish Journal of Gastroenterology},
  year = {2023},
  doi = {10.5152/tjg.2023.22239}
}
Kostenlos starten →